This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for GENFIT S.A. Unsponsored ADR (GNFT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
What Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy Stock
by Zacks Equity Research
GENFIT S.A. Unsponsored ADR (GNFT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Can GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 78.9% upside potential for GENFIT S.A. Unsponsored ADR (GNFT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in GENFIT S.A. Unsponsored ADR (GNFT)? Wall Street Analysts Think 60%
by Zacks Equity Research
The mean of analysts' price targets for GENFIT S.A. Unsponsored ADR (GNFT) points to a 59.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Intercept (ICPT) Posts New Positive Results on NASH Drug
by Zacks Equity Research
Intercept (ICPT) releases new favorable outcome on OCA from the REGENERATE study, which evaluated patients with liver fibrosis due to NASH.
Intercept's (ICPT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) reports better-than-expected results for the second quarter of 2020.
Intercept Slumps as the FDA Issues CRL to NASH Candidate
by Zacks Equity Research
Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
Is Genfit (GNFT) Stock a Solid Choice Right Now
by Zacks Equity Research
Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Intercept Down on Postponement of AdCom Meet for NASH Drug
by Zacks.com
The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.
Intercept's (ICPT) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intercept (ICPT) reports better-than-expected results for the first quarter of 2020 on solid Ocaliva sales.
Why Genfit (GNFT) Stock Might be a Great Pick
by Zacks Equity Research
Genfit (GNFT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Genfit Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genfit.
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.
Zacks.com featured highlights include: Teledyne, Genfit, Shoe Carnival, ZTO and GCI
by Zacks Equity Research
Zacks.com featured highlights include: Teledyne, Genfit, Shoe Carnival, ZTO and GCI
5 Stocks to Buy on New Analyst Coverage
by Shrabana Mukherjee
Higher analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Top Ranked Momentum Stocks to Buy for April 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 25th
Gilead to Collaborate with Novo Nordisk for NASH Treatment
by Zacks Equity Research
Gilead Sciences (GILD) will collaborate with Novo Nordisk to develop treatments for liver disease, NASH.